Unravelling the Significance of Cystatin C and Bunina Bodies in Amyotrophic Lateral Sclerosis Pathogenesis
Neuropathology and Applied Neurobiology · 2026
DOI: 10.1111/nan.70083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropathology and Applied Neurobiology, 2026. Verfasst von Sarah M Granger und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Cystatin C, Inclusion Bodies, Motor Neurons. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Motor Neurone Disease Association.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a fatal neurodegenerative disease primarily affecting motor neurons. Two key protein inclusions found in lower motor neurons serve as neuropathological hallmarks of the disease in human tissue: the TDP43‐positive inclusion and the cystatin C‐positive Bunina body. Despite their diagnostic specificity and presence in most sporadic and familial ALS cases, Bunina bodies remain poorly understood, and their true prevalence is likely underestimated. The co‐occurrence of the Bunina body and the TDP43 inclusion may provide valuable insights into the development of TDP43 pathology in ALS. Thorough characterisation of the Bunina body is needed to understand this interplay and the broader pathomechanisms of disease. This review examines our current knowledge of Bunina bodies and the biochemical properties of cystatin C that may promote its aggregation. Sequestration and aggregation of cystatin C into Bunina bodies may diminish its neuroprotective functions, including cysteine protease inhibition, autophagy induction and anti‐amyloidogenic activity, thereby contributing to ALS pathogenesis. This review also evaluates findings from human post‐mortem tissue and ALS disease models, discussing the value and limitations of these models in the context of Bunina bodies and TDP43 pathology. Finally, we discuss cystatin C's use as a biomarker and its therapeutic potential. A deeper understanding of cystatin C biology, its relationship with TDP43 pathology and improved ALS models will be essential for determining whether targeting cystatin C could provide a viable avenue for future ALS therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Sheffield, Sheffield, UK.
- Department of Pathology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
- Arctic Therapeutics, Reykjavik, Iceland.
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
ORCID-Profile: Sarah M Granger, Asbjorg Osk Snorradottir, J Robin Highley
Förderung
- Motor Neurone Disease Association
Zitieren
APA
Granger, S. M., Staniforth, R. A., Snorradottir, A. O., Cooper-Knock, J., De Vos, K. J., & Highley, J. R. (2026). Unravelling the Significance of Cystatin C and Bunina Bodies in Amyotrophic Lateral Sclerosis Pathogenesis. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.70083
Vancouver
Granger SM, Staniforth RA, Snorradottir AO, Cooper-Knock J, De Vos KJ, Highley JR. Unravelling the Significance of Cystatin C and Bunina Bodies in Amyotrophic Lateral Sclerosis Pathogenesis. Neuropathology and Applied Neurobiology. 2026. doi:10.1111/nan.70083
BibTeX
@article{Granger2026,
author = {Granger, Sarah M and Staniforth, Rosemary A and Snorradottir, Asbjorg Osk and Cooper-Knock, Johnathan and De Vos, Kurt J and Highley, J Robin},
title = {Unravelling the Significance of Cystatin C and Bunina Bodies in Amyotrophic Lateral Sclerosis Pathogenesis},
journal = {Neuropathology and Applied Neurobiology},
year = {2026},
doi = {10.1111/nan.70083}
}
EUVIMED